Open in app

Government examining the dangers and advantages of Merck's Covid Medication.

img-1
Total Views:
32
img-1
Total Likes:
1
img-1
Published By:
Peeyush Ghalot
img-1
Published On:
27-12-2021

Merck's Covid medication Antiviral Covid-19 tablet Molnupiravir, which gained emergency use authorization (EUA) from the US FDA, is expected to be narrowly recommended in India by a government panel considering the risks and benefits. In light of this, the SEC inquired about the details of risk mitigation strategy and a particular group of covid patients who are expected to obtain the benefit of the treatment, for which the medicine may be prescribed. The United States Food and Drug Administration has approved the use of EUA for the treatment of mild-to-moderate coronavirus infection in those who are at high risk of developing severe Covid-19, which might lead to hospitalisation or death. Molnupiravir is not approved for usage in patients under 18 because it might damage bone and cartilage formation. Molnupiravir, developed by MSD and Ridgeback Biotherapeutics, prevents the SARS-CoV-2 virus from replicating further by introducing errors into its genetic code. Molnupiravir is taken orally in four 200 milligram capsules every 12 hours for five days, totalling 40 capsules. Molnupiravir should not be taken for more than five days in a row.

(Picture: - WFXG)

Reference: - https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/govt-panel-weighing-risks-and-benefits-of-mercks-covid-drug/articleshow/88485075.cms?from=mdr